Introduction {#Sec1}
============

Mastocytosis comprises a heterogeneous spectrum of diseases characterized by a range of local and systemic symptoms. The current World Health Organization (WHO) classification, updated in 2008, differentiates one exclusively cutaneous form from the systemic forms of mastocytosis \[[@CR1]--[@CR3]\]. Cutaneous mastocytosis (CM) is a condition classified according to clinical symptoms and identified by an abnormal accumulation of mast cells limited to the skin. Clinically, CM is divided into three main variants: maculopapular CM (or urticaria pigmentosa), characterized by disseminated small patches, papules, and plaques; diffuse CM, affecting large areas of the skin with yellow-red erythroderma-like, diffuse doughy-firm swellings and solitary mastocytoma, partly characterized by blistering and found predominantly in children. The much rarer forms are defined as the plaque form, the nodular form, and telangiectasia macularis eruptiva perstans. These disorders do not represent independent variants in the WHO classification and are assigned to maculopapular CM \[[@CR1]--[@CR4]\].

CM has been diagnosed in patients with disseminated bullous lesions, plaques, nodules, and other clinical presentations such as localized mastocytosis, solitary and multiple mastocytomas, and some other unusual morphologies \[[@CR4], [@CR5]\].

We present a 3-year-long follow-up of a child with skin lesions of various morphologies and sizes, continuous blistering, and frequent flushing during the first 6 months of his life. Successful treatment was achieved with a short methylprednisolone course and subsequent intermittent H1 receptor antagonist and topical treatments.

Case Report {#Sec2}
===========

A 6-month-old male infant was referred with different types of skin lesions, persistent blistering, and frequent spontaneous flushing since birth. The child did not have any physical or psychomotor disturbances. No significant family or antenatal history data existed. Intermittent courses with oral H1 blockers and topical antibiotics and corticosteroids had been administered without improvement.

On admission, vital signs and chest and abdomen examinations were unremarkable, while hepatosplenomegaly and lymphadenopathy were absent. A variety of skin lesions (reddish-brown, partially with peau d'orange appearance, macules, papules, plaques, and nodules), sized 4--65 mm, were distributed on the neck, trunk, buttocks, and extremities. Tense bullae, erosions, and crusts were revealed to overlay plaque surfaces (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}a). Darier's sign was demonstrated (Fig. [2](#Fig2){ref-type="fig"}b). Oral mucosa was not affected. Within the first 2 days, we observed several flushing episodes, unprovoked by any triggering factors.Fig. 1One of the multiple *reddish-brown* plaques with peau d'orange appearanceFig. 2**a** Nodular lesion on the neck, **b** Darier's sign

Laboratory findings did not disclose hematologic, biochemical, or liver function abnormalities. Serum tryptase level (STL) was 11.8 ng/ml (reference range \<11.4 ng/ml). A biopsy taken from an elevated plaque with vesiculation revealed melanin in the basal/suprabasal layer, subepidermal bulla, dense mast cell infiltration, and some eosinophils in the dermis (Fig. [3](#Fig3){ref-type="fig"}a). Immunohistochemical staining for CD117 antibody was positive (Fig. [3](#Fig3){ref-type="fig"}b). Toluidine blue and Giemsa stainings showed metachromatic granules in the cytoplasm of the infiltrating cells (Fig. [4](#Fig4){ref-type="fig"}a, b). The pediatric consultation did not reveal systemic symptoms.Fig. 3**a** Subepidermal bulla and dermal infiltration (H&E; ×200), **b** CD117-positive mast cell infiltration (×400)Fig. 4**a** Toluidine blue (×200) and **b** Giemsa (×400) staining of mast cell dermal infiltration

The patient was initially treated with methylprednisolone 0.6 mg/kg once daily (o.d.) intramuscularly (3 days), oral levocetirizine 1.25 mg o.d, 2% topical fusidic acid, and 0.1% betamethasone valerate cream. Subsequently, the dose of methylprednisolone was tapered, given orally (0.5 mg/kg o.d \[4 days\], 0.5 mg/kg every other day \[2 weeks\], 0.5 mg/kg twice a week \[2 weeks\]) and stopped. After 10 days, levocetirizine was replaced with ketotifen 0.05 mg/kg twice daily for eight more weeks and the cream was replaced with 1% hydrocortisone cream for a month. The child was closely followed up during the treatment. His symptoms improved remarkably. There were no adverse effects of the therapy. Over the following 3 years, the clinical manifestations were successfully managed with intermittent ketotifen and topical hydrocortisone treatments. Parents were counseled on the avoidance of triggering factors for mediator release. At the last follow-up (3.5 years of age), only a few pale-brownish macules were seen with no blistering or isolated flushing episodes. The STL declined to 7.2 ng/ml. For 3 years the patient did not show any symptoms consistent with systemic mastocytosis.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from the parent for the child being included in the study and for the publication of the patient photographs.

Discussion {#Sec3}
==========

The diversity of CM skin manifestations is evident when reviewing the literature. With regard to cutaneous lesions, our case seems to belong to the maculopapular and nodular CM, showing a range of lesions of various sizes and morphologies. Such varied lesions are encountered more often in pediatric than in adult CM where a more uniform presentation of small patches and papules is common \[[@CR1]--[@CR5]\].

The bullous form of mastocytosis is a rare, morbid condition typically encountered in young children \[[@CR2]\]. Episodic blistering has been reported in maculopapular CM, which usually occurs after stroking or rubbing of the lesional skin and rarely appears spontaneously \[[@CR4]\]. There are also reports of nodular forms with occasional blistering as well as predominant bullous variants of CM. In fact, the long-living bullous manifestations are characteristic of the diffuse CM \[[@CR3]--[@CR5]\]. It is interesting that in our case, the varied skin lesions, not corresponding to diffuse CM, were associated with an uninterrupted bulla formation for half a year and no improvement with H1 receptor blockers or topical corticosteroids/antibiotics.

In our case, the flushing episodes were very frequent, spontaneous, and not induced by any precipitating factor (ambient temperature, food, exercise, stress, medication, etc.). This was the only systemic clinical symptom. No other signs of internal organ involvement were revealed except for an STL of 11.8 ng/ml. This is not indicative of systemic mastocytosis, where the STL reference value is \>20 ng/ml. This slightly elevated STL might relate to flushing as a single symptom of the mast cell mediator release. It is observed more often in patients with systemic involvement, but may also occur in those with purely cutaneous manifestations \[[@CR1]--[@CR6]\].

In our case, the diagnosis of CM was made based on clinical manifestations, Darier's sign, and histopathological and immunohistochemical findings (anti-c-kit/CD117 with a high specificity and sensitivity for mast cells). It is widely accepted that growth and differentiation and proliferation of mast cells are controlled by the tyrosine kinase receptor *c*-*Kit* (CD117) and its ligand stem cell factor. It is also controlled by other cytokines such as IL-4, IL-6, IL-10, and IL-13 \[[@CR1], [@CR2]\]. Recent genetic studies have identified new proteins (Lin28b) that are of interest in mast cell disease \[[@CR7]\].

Adequate management during the early phase of CM in children may prevent potential complications. Counseling of patients/parents is important to avoid mediator release precipitating factors and treat mast cell mediator release symptoms. CM remissions have been reported following treatments with anti-mediator drugs such as H1 and H2 receptor antagonists and cromolyn sodium (oral and topical). Topical/intralesional corticosteroids, phototherapy, and topical calcineurin inhibitors may be useful \[[@CR8]--[@CR10]\].

In our case, considering the previous therapy failure, we applied a short course of methylprednisolone, combined with an H1 receptor blocker (levocetirizine) and topical mid-potency corticosteroid. This was followed by intermittent H1 receptor blocker (ketotifen) and topical hydrocortisone courses. This treatment reduced the patient's persistent blistering and the frequency of flushing episodes. No adverse events occurred. The 3-year-long follow-up demonstrated that our approach to a refractory, though not severe, clinical form of CM can be to the patient's benefit. Of note, neither low-dose H2 receptor blockers (for pediatric use) nor sodium cromoglycate are available in Bulgaria.

The debate between more or less aggressive management options for pediatric CM continues. Systemic and topical corticosteroids have demonstrated good therapeutic results in some cases of bullous mastocytosis, as reported in the literature \[[@CR11], [@CR12]\].

Conclusion {#Sec4}
==========

Childhood CM usually has a benign course and most of the cases resolve by puberty \[[@CR2], [@CR3]\]. With proper treatment and family education on avoiding triggering factors, gradual resolution of both skin lesions and mast cell-mediated symptoms may be observed. Despite the lack of systemic involvement, some patients with CM may develop skin manifestations that are difficult to control. Therefore, follow-up with rigorous evaluation and relevant management is required for each individual case.
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